AstraZeneca (GB:AZN) has released an update.
AstraZeneca’s drug Fasenra has received FDA approval in the U.S. for treating eosinophilic granulomatosis with polyangiitis (EGPA), a rare, life-threatening immune-mediated vasculitis. Grounded in the successful MANDARA trial, Fasenra showed that nearly 60% of patients achieved remission, and 41% could cease oral corticosteroid use, offering a significant new treatment option for the approximately 15,000 U.S. patients with this rare disease.
For further insights into GB:AZN stock, check out TipRanks’ Stock Analysis page.
